FBLG · Fibrobiologics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.95M | - | $2.79M | $2.04M | $1.78M | - | $571.0K | $975.0K | $960.0K | - |
| SG&A | $2.12M | - | $2.25M | $2.45M | $2.75M | - | $2.14M | $1.55M | $2.49M | - |
| Total Operating Expenses | $5.07M | - | $5.04M | $4.49M | $4.53M | - | $3.35M | $2.09M | $3.45M | - |
| D&A | $66.0K | - | $65.0K | $60.0K | $53.0K | - | $38.0K | $2.0K | $35.0K | - |
| Operating Income | ($5.07M) | - | ($5.04M) | ($4.49M) | ($4.53M) | - | ($3.35M) | ($3.22M) | ($3.45M) | - |
| Interest Expense | $0 | $200.0K | $0 | $5.0K | $4.0K | - | $5.0K | $10.0K | $4.0K | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.00M) | - | ($5.78M) | ($4.66M) | ($4.97M) | - | ($2.19M) | $898.0K | ($8.46M) | - |
| EPS - Basic | ($1.33) | - | ($2.60) | ($2.40) | ($2.80) | - | ($0.20) | ($1.60) | ($5.40) | - |
| EPS - Diluted | ($1.33) | - | ($2.60) | ($2.40) | ($2.80) | - | ($0.20) | $0.60 | ($5.40) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.48M | $4.89M | $4.87M | $8.85M | $8.67M | $13.98M | $7.83M | $5.97M | $8.16M | $9.16M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $2.90M | $6.35M | $5.24M | $10.18M | $9.33M | $14.23M | $8.20M | $6.51M | $8.92M | $9.21M |
| Total Assets | $5.94M | $9.62M | $8.74M | $13.91M | $11.43M | $16.45M | $10.47M | $8.91M | $11.40M | $11.82M |
| Current Liabilities | $1.83M | $1.76M | $6.72M | $10.96M | $8.21M | $12.73M | $6.68M | $10.13M | $13.98M | $9.18M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.34M | $3.46M | $8.62M | $13.05M | $9.08M | $13.71M | $7.73M | $11.30M | $15.26M | $10.57M |
| Stockholders' Equity | $2.60M | $6.16M | $125.0K | $860.0K | $2.35M | $2.73M | $2.74M | $11.35M | ($3.86M) | $1.25M |
| Retained Earnings | ($59.16M) | ($54.16M) | ($50.92M) | ($45.14M) | ($40.48M) | ($35.52M) | ($32.42M) | ($31.92M) | ($32.82M) | ($24.36M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.36M) | - | - | - | ($5.28M) | - | - | - | ($4.28M) | - |
| Investing Cash Flow | $0 | - | - | - | ($43.0K) | - | - | - | ($8.0K) | - |
| Financing Cash Flow | $0 | - | - | - | - | - | - | - | $3.28M | - |
| CapEx | $0 | - | - | - | $43.0K | - | - | - | $8.0K | - |
| Free Cash Flow | ($4.36M) | - | - | - | ($5.32M) | - | - | - | ($4.28M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.87 | - | - | - | 1.07 | - | - | - | 0.51 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -84.2% | - | -66.1% | -33.5% | -43.5% | - | -20.9% | 10.1% | -74.2% | - |
| Return on equity | -192.3% | - | -4622.4% | -541.6% | -211.3% | - | -80.1% | 7.9% | 219.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.59 | 3.61 | 0.78 | 0.93 | 1.14 | 1.12 | 1.23 | 0.64 | 0.64 | 1.00 |
| Quick ratio | 1.59 | 3.61 | 0.78 | 0.93 | 1.14 | 1.12 | 1.23 | 0.64 | 0.64 | 1.00 |
| Cash ratio | 0.81 | 2.78 | 0.72 | 0.81 | 1.06 | 1.10 | 1.17 | 0.59 | 0.58 | 1.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | -898.0x | -1132.8x | - | -670.4x | -322.4x | -862.5x | - |
| Equity multiplier | 2.28 | 1.56 | 69.95 | 16.17 | 4.86 | 6.01 | 3.82 | 0.78 | -2.95 | 9.43 |
| Liabilities / Assets | 0.56 | 0.36 | 0.99 | 0.94 | 0.79 | 0.83 | 0.74 | 1.27 | 1.34 | 0.89 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | 166.3x | - | - |
| P / B | 1.9x | - | 3762.8x | 558.9x | 280.9x | - | 756.8x | 248.2x | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -11.9% | - | -50.3% | -39.3% | -31.3% | - | - | - | - | - |
| Net income growth (YoY) | -0.7% | - | -163.5% | - | 41.3% | - | - | - | - | - |
| EPS growth (YoY) | 52.5% | - | -1200.0% | - | 48.1% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 17.9% | - | - | - | -24.2% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 10.6% | 125.1% | -95.4% | -92.4% | - | 118.3% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing FibroBiologics against the 5 most active filers in the same SIC group.